Viatris Will Tread A Different Path

Mylan-Upjohn Combination Neither Pure Generics Nor Big Pharma Player

By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.

Choices
The Viatris entity formed by merging Mylan and Upjohn will aim to chart a path between generics and big pharma • Source: Shutterstock

More from Deals

More from Business